Hepatic complications contribute to morbidity and mortality after allogeneic hemopoietic SCT. Liver Doppler ultrasound and elastography represent promising methods for pretransplant risk assessment and early detection of complications. Ultrasound (liver and spleen size, liver perfusion) and elastography (transient elastography (TE); right liver lobe acoustic radiation force impulse imaging (r-ARFI); left liver lobe ARFI (l-ARFI)) were prospectively evaluated in patients with indications for allo-SCT. Measurements were performed before and repeatedly after SCT. Results were compared with the incidence of life-threatening complications and death during the first 150 days after SCT. Of 59 included patients, 16 suffered from major complications and 9 of them died within the follow-up period. At baseline, liver and spleen size, liver perfusion, TE and r-ARFI did not differ significantly between patients with and without severe complications. In contrast, l-ARFI was significantly elevated in patients who later developed severe complications (1.58 ± 0.30 m/s vs 1.37 ± 0.27 m/s, P = 0.030). After SCT, l-ARFI values remained elevated and TE showed increasing liver stiffness in patients with complications. The value of conventional liver ultrasound for prediction of severe SCT complications is limited. Increased values for TE and l-ARFI are associated with severe SCT complications and demand further evaluation.
INTRODUCTION
Hepatic GvHD, drug-induced liver injury and veno-occlusive disease (VOD) contribute to non-relapse morbidity and mortality during the early phase after allo-SCT. 1 In addition, systemic complications of SCT including disseminated infection and cardiopulmonary distress can alter hepatic function.
Therefore, liver-specific predictive and diagnostic parameters for risk stratification in patients undergoing stem cell therapy are required:
2 B-mode ultrasound can serve as a screening test for detection of obstructive cholestasis and liver cirrhosis before SCT, but may lack sensitivity for early stages of liver fibrosis. 3 Recently, the hepatic artery resistance index-a measure of the arterial perfusion profile-has been suggested as a potential prognostic parameter for prediction of SCT-associated hepatic complications but deserves further evaluation. 4 Risk scores such as the hemopoietic cell transplantation-comorbidity index (HCT-CI) predict non-relapse 2-year mortality with good accuracy but have not been evaluated for prediction of short-term outcomes. 2, 5 Liver stiffness measurement (LSM) is an established modality for noninvasive staging of fibrosis in chronic liver diseases. 6 The ultrasound-based techniques, transient elastography (TE) and acoustic radiation force impulse imaging (ARFI), assess liver stiffness by tracking mechanical impulses with ultrasound signals. Results can be obtained within few minutes and show a high accuracy for detection of advanced liver fibrosis and cirrhosis. 7 Furthermore, LSM can be used for characterization of hepatic necro-inflammation and cholestasis in the absence of fibrosis. [8] [9] [10] In this line, preliminary data indicate a correlation of liver stiffness and liver toxicity following hematopoietic SCT. 11 We performed a prospective study to characterize the diagnostic value of B-mode, Doppler liver ultrasound and LSM for prediction and diagnosis of severe complications with and without liver involvement in SCT patients.
PATIENTS AND METHODS

Patients and study design
The present study was performed in accordance with the ethical guidelines of the Helsinki Declaration and was approved by the local ethics committee (registration number 032-11-24012011). All study participants provided written informed consent.
Between February 2011 and July 2012, patients with indications for allo-SCT due to hematological disorders were consecutively included in the study. Pregnancy and age o18 years were regarded as exclusion criteria. Before undergoing conditioning therapy, patients were evaluated for possible contraindications including presence of advanced liver disease by medical history, physical examination, laboratory tests including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, gamma-glutamyltransferase, blood cell count, INR (International normalized ratio) and hepatitis viruses. In addition, the HCT-CI was calculated according to the published algorithm. 5 For ultrasound and elastography assessment, patients were scheduled for four study examinations: (i) baseline examination ( o10 weeks before SCT and before beginining conditioning therapy) and (ii) three follow-up examinations at 2-3 weeks, 4-8 weeks and 12-20 weeks after SCT. To minimize the risk of nosocomial infections, single follow-up examinations were canceled in the case of severe neutropenia requiring reverse isolation or needing intensive care treatment.
Data on clinical course, liver function tests and outcome were collected until day 150 after SCT. Patients not available for follow-up were excluded from the final analysis.
Definition of complications after SCT Hepatic GvHD was defined as abnormal results of liver function tests with cholestatic pattern with or without involvement of other organs after exclusion of obstructive jaundice by ultrasound. 12, 13 Occurrence of acute hepatitis predominantly characterized by elevated levels of aminotransferases in temporal association with hepatotoxic drug administration was classified as drug-induced liver injury. 14 The diagnosis of VOD was based on the McDonald criteria comprising unexplained weight gain or ascites, hepatomegaly associated with tenderness of the right upper abdomen and jaundice. 15 VOD diagnosis was also established in the case of late onset of McDonald criteria >20 days after SCT unless symptoms could be explained by an alternative diagnosis. 16 For final analysis, the study cohort was stratified for the occurrence of severe (life threatening) complications and death during the first 150 days after SCT. This definition was based on the common terminology criteria (CTC) for adverse events Vs 4: 17 Patients were either assigned to the group without severe complications (CTC grades 0-3) or classified as lifethreatening complications or death (CTC grades 4 and 5).
Ultrasound assessment and elastography
Ultrasound and elastography assessment were performed at the same time point by one out of four experienced operators (TK, JW, MT and VK). Patients were examined in a supine position with the right arm elevated above the head after fasting for at least 3 h.
B-mode, Doppler ultrasound parameters and ARFI measurements were recorded using a conventional convex ultrasound transducer (Acuson S2000, Siemens Medical Solutions, Mountain View, CA, USA, probe 4C1): size of both liver lobes, portal venous flow velocity and hepatic artery resistive index at an extrahepatic level, 18 spleen size (longest diameter) and liver capsule-to-skin distance at the site of LSM measurement. Measurements were obtained during a short breath hold avoiding deep inspiration.
Measurements of shear-wave velocity (ARFI) were performed at two different sites in an area of homogenous tissue in resting respiratory position as described before: 19 (i) right liver lobe ARFI (r-ARFI) through the intercostal space and (ii) left liver lobe ARFI (l-ARFI) in the epigastric region in the median line. Ten valid measurements at each site were required. The ARFI success rate was calculated as the ratio between the valid and the total number of measurements. The median value of each measuring site was used for further analysis. In cases of a success rate below 60% the result was regarded as invalid and excluded from further analysis. 7, 19 TE (Fibroscan, Echosens, Paris, France) was performed in a right intercostal space in the resting respiratory position. Ten valid measurements were taken with the M-probe according to the manufacturer's recommendation. Patients with an interquartile range exceeding one-third of the median value or a success rate below 60% were considered as invalid and excluded from further analysis. 20 In cases of M-probe failure (success rate o60%), the measurement was repeated using the XL-probe. 21 
Statistical analysis
Data were collected in a Microsoft Excel file (Microsoft Corporation, Redmond, WA, USA). Statistical analyses were conducted by using MedCalc 12.1 (MedCalc Software, Ostend, Belgium). Fisher's exact test and χ 2 -test were used to test for association of variables. Nonparametric tests were chosen to compare median values of two independent samples (Mann-Whitney U-test) or groups (Kruskal-Wallis test). Diagnostic performance of ultrasound and elastography methods were evaluated using receiver operating characteristic curves. The probabilities of a true-positive (sensitivity) and a true-negative (specificity) assessment with selected cutoff values were determined, and the area under the receiver operating characteristics curve was calculated. All tests were two sided. A P-value o0.05 indicated a significant difference or correlation.
RESULTS
Characteristics of the study cohort and clinical outcome Patients (n = 73) were screened for the study and 59 were included in the final analysis (Table 1) . Reasons for exclusion were withdrawal of consent (n = 2), contraindication for SCT or donor unavailability (n = 7) and missing follow-up data (n = 5). Abbreviations: CTC = common toxicity criteria; HCT-CI = hemopoietic cell transplantation-comorbidity index; MDS = myelodysplastic syndrome. a Values are presented as mean ± s.d.
b n = 52 (88%) received total body irradiation.
Value of liver elastography in SCT T Karlas et al N = 43 patients had no or only mild-to-moderate therapyassociated complications without severe involvement of the liver during the follow-up period (CTC grades 0-3). In seven cases, major complications (CTC grade 4) occurred: n = 4 acute GvHD and/or severe liver toxicity; n = 2 VOD; one case with transplant rejection (day of complication onset after SCT: median 64, range 9-121). Nine patients died (CTC grade 5) within 150 days after allo-SCT (median day of death 92, range 55-138). Of these, six had refractory or relapsing disease (median day of relapse 27, range 0-111) and three died of multiorgan failure in association with infection. In four of the deceased patients, severe hepatic complications contributed to the fatal outcome (acute liver failure n = 3, VOD in one case). Preconditioning characteristics (sex, age, body mass index, liver function tests and diagnosis) were comparable between the two subgroups ( Table 1) .
Baseline laboratory values, ultrasound parameters and liver elastography Blood count revealed lower Hb concentration and platelet count in patients with impaired post-transplant outcome (CTC grades 4 and 5) ( Table 2 ). Liver and spleen size, liver perfusion and liver function tests did not differ significantly between patients with and without severe SCT complications at baseline examination (Table 2) .
ARFI was feasible in almost all patients (r-ARFI in 100% and l-ARFI in 97%), whereas TE showed a higher failure rate: measurement with the M-probe was not successful in 18 (30.5%) patients at baseline examination owing to a low success rate. Despite the use of the TE XL probe in such cases, no valid TE result could be obtained in 14% of patients at baseline examination (n = 8 with high interquartile range, n = 1 with low success rate). Failure of TE measurement was associated with higher body mass index (27.8 ± 4.5 kg/m 2 vs 23.6 ± 3.6 kg/m 2 ; Po 0.001) and skin-to-liver capsule distance (22.4 ± 4.2 mm vs 16.8 ± 3.7 mm; P o 0.001) at the site of LSM.
At baseline, r-ARFI (1.13 ± 0.31 m/s vs 1.17 ± 0.33 m/s, P = 0.341) did not detect significant differences between the patient groups ( Figure 1 ). TE was also not elevated in the cohort with severe SCT complications (5.6 ± 2.2 kPa vs 4.6 ± 1.5 kPa, P = 0.151), although cases with severe hepatic affection (liver GvHD, VOD and liver failure: n = 5 with valid TE baseline results) had slightly elevated baseline TE values (6.2 ± 1.5 kPa vs 4.7 ± 1.7 kPa, P = 0.043).
In contrast to r-ARFI findings, baseline l-ARFI values were significantly elevated in patients that later developed severe complications after SCT (1.58 ± 0.30 m/s vs 1.37 ± 0.27 m/s, P = 0.030). Receiver operating characteristic curve analysis revealed a high sensitivity for prediction of CTC grades 4 and 5 complications by l-ARFI (Table 3) . However, the diagnostic accuracy was only moderate as a result of the high range of individual l-ARFI values in the event group (1.26-2.30 m/s). The negative-predictive value at a cutoff of >1.24 m/s was 100%. In consequence, all patients with l-ARFI o 1.25 (n = 14; 25% of cases with valid l-ARFI) remained free of severe complications after SCT.
Laboratory values, conventional ultrasound and liver elastography after SCT After SCT, liver enzymes (alkaline phosphatase and gammaglutamyltransferase) were significantly elevated in patients with complications, whereas the liver and spleen size and portal venous flow remained unchanged (Table 2) .
TE follow-up was impaired in two cases with valid baseline result (LSM with high interquartile range, respectively), whereas follow-up ARFI was feasible in all patients with valid baseline measurement.
Overall, TE and ARFI of both liver lobes indicated a trend to increasing LSM values after SCT in all patients (Figure 1 ). However, during early follow-up, TE and r-ARFI were not associated with the occurrence of major complications or death. In contrast, elevation of l-ARFI persisted in CTC grades 4 and 5 patients. In the further course, remaining patients with CTC grades 4 and 5 had higher TE values compared with baseline examination and with patients with CTC grades 0-3, whereas no difference could be detected with r-ARFI (Figure 1 ).
Comparison of elastography results with HCT-CI HCT-CI scores did not differ significantly between patients with and without severe complications (Table 1 ). Baseline elastography values of patients with HCT-CI ⩾ 3 (n = 13) were compared with the remaining cohort with lower HCT-CI (n = 46): r-ARFI (1.21 ± 0.29 m/s vs 1.15 ± 0.34 m/s), l-ARFI (1.53 ± 0.34 m/s vs 1.40 ± 0.28 m/s) and TE (4.9 ± 1.8 kPa vs 4.9 ± 1.7 kPa) did not differ between these two groups (P>0.05, respectively).
DISCUSSION
Complications such as hepatic GvHD, drug-induced liver injury and VOD are a frequent finding after allo-SCT and account for a significant amount of non-relapse morbidity and mortality in affected patients during the early phase after SCT. 1 The incidence of such events and further severe complications in our study was rather similar to observations of larger trials 1, 22 Value of liver elastography in SCT T Karlas et al and, therefore, our cohort may be regarded as representative of the spectrum of complications in the early phase after allo-SCT.
Because of the high frequency of therapy-related morbidity and mortality, risk assessment is crucial for decision making when allo-SCT is considered as a treatment option in patients with hematological disorders. 2, 5 Previously, Song et al. 4 described the pretransplant measurement of hepatic artery resistance index as a potential tool for prediction of hepatic GvHD. 4 In our study, however, conventional B-mode ultrasound assessment of liver and spleen size, and Doppler analyses of hepatic perfusion were not useful for prediction and detection of severe complications after allo-SCT. The discrepancies between our data and the findings from Song et al. 4 may be explained by a rather unspecific definition of hepatic GvHD in the latter patient cohort and a high incidence of further hepatic complications. As the frequency of therapy-related severe liver dysfunction in our study corresponds to much larger trials, 1,22 assessment of hepatic arterial perfusion for prediction of GvHD may only have a minor role in clinical routine.
During the last decade, LSM with ARFI and TE has been established as a diagnostic option for noninvasive estimation of liver fibrosis and identification of patients with advanced hepatic diseases. 7, 23 Recently, the potential clinical value of liver elastography for risk stratification in patients with hematological disorders has been demonstrated by Auberger et al., 11 who described an increased rate of liver toxicity following hematopoietic SCT in patients with elevated pretransplant liver stiffness. In this analysis, 18% of cases showed baseline TE values >7.71 kPa suggestive for fibrosis. 11, 24 In contrast to these findings, the prevalence of elevated LSM in our cohort was much lower and only two patients had TE results above the cutoff for advanced liver fibrosis. Consequently, both r-ARFI and TE at baseline did not exhibit any value with respect to prediction of complication after SCT.
Surprisingly, baseline l-ARFI was significantly elevated in cases that suffered from complications or died during the observation period after SCT (Figure 1) . Further analysis identified a subgroup (25% of all cases) with baseline l-ARFI values below 1.25 m/s: none of these patients developed life-threatening complications after SCT. Therefore, l-ARFI could serve as an additional screening method in the evaluation of SCT candidates. However, left liver lobe elastography is not yet considered as a standard procedure and its clinical value for fibrosis detection has been discussed critically. 19, 23, 25 Further trials including larger patient samples are required for validation of our findings. These studies should also assess the correlation of l-ARFI with central venous pressure and right heart function in order to refine the standardization of the measurement process and to improve the method's accuracy.
A general increase of liver stiffness after SCT, which was observed in the majority of our patients, is probably linked to Abbreviations: ARFI = acoustic radiation force impulse imaging; AUC = area under the receiver operating characteristics curve; NPV = negativepredictive value; PPV = positive-predictive value. Sensitivity and specificity were determined at the cutoff level with Youden index maximum. a Significant difference from 0.5 (Delong-method). Significant difference is indicated in bold.
Value of liver elastography in SCT T Karlas et al hepatic edema and inflammation as a result of therapy toxicity and hemodynamic changes. 8, 9, 26, 27 These findings correspond with data of increased liver stiffness in critically ill non-cirrhotic patients. 28 Beyond that, TE could discriminate selected cases with severe complications in the later post-transplant course probably by reflecting severe acute hepatic injury in cases with liver affection 29 and cardiopulmonary distress in those without hepatic involvement. 26, 28 These results are in line with previous case series that reported elevated LSM in patients with acute liver disease in the absence of advanced fibrosis. 27, 29 Unfortunately, the diagnostic performance of TE was limited by a rather high number of invalid measurements, which occurred more frequently in our cohort than in biopsy-controlled studies focusing on hepatic fibrosis. 20 These findings reflect the limited feasibility of TE in patients with severe systemic disorders. 28 The use of the XL-probe may partially overcome this problem especially in cases with obesity, 21 but potential discordance between M-and XL-probes results remains an unsolved problem of this technique and may have impaired diagnostic accuracy in our study as well. 30 In contrast to TE, ARFI values of the right liver lobe did not show any diagnostic value, which may be explained by the smaller amount of tissue volume assessed by ARFI compared with TE. An inhomogeneous pattern of ARFI in VOD patients has been previously reported in a case series by Fontanilla et al. 31 Therefore, a larger liver sample volume will more likely reveal elevated LSM results in such patients. This limitation and further associated technical aspects may limit the methods sensitivity for hepatocellular edema and inflammation. 6, 23 The sample size of our pilot study neither allowed a subgroup analysis of cases with disease relapse nor stratifying patients for the occurrence of distinct hepatic complications. However, relapse of the underlying hematological disorder may also involve the hepatobiliary system and hence mimic hepatic complications. Besides, severe SCT side effects occurred frequently in patients with relapsing disease thus rendering distinction between both conditions difficult. Moreover, criteria for GvHD, drug-induced liver injury and VOD show a considerable overlap and diagnosis depends on evaluation of complex clinical circumstances in individual cases. Furthermore, complications of SCT, especially infection, septicemia and shock with organ failure, frequently affect liver function. For this reason, we decided to stratify the study cohort for any severe therapy-related event or death during the early course after SCT. 17 Hence, our findings are based on categorization of evident clinical outcomes and future research is required to define the potential diagnostic benefit of LSM in patients undergoing stem cell therapy. Furthermore, prompt examination of study patients was not always possible when complications occurred, especially in patients requiring intensive care (ventilation and catecholamine medication) or cases with prolonged neutropenia. Therefore, the actual increase of LSM may have been higher at the time of complication onset. In this line, further research should verify the diagnostic benefit of LSM by investigating whether increasing liver stiffness precedes clinical symptoms of (preventable) SCT complications in selected cases.
In conclusion, the correlation of LSM with the clinical outcome of hematopoietic stem cell therapy demonstrates the potential clinical value of liver elastography beyond the staging of liver fibrosis. In the present pilot study, patients with pretransplant l-ARFI below 1.25 m/sec remained free of severe complications after allo-SCT. Therefore, l-ARFI may be used as complementary option for risk stratification in patients with hematological disorders before SCT is performed. At the moment this remains an interesting hypothesis because underlying mechanisms of tissue stiffness alterations in the left liver lobe are not yet completely elucidated and our findings will have to be confirmed in larger studies. TE may represent an additional diagnostic parameter for patients with suspected post-transplant hepatic injury and deserves further evaluation in SCT settings.
